Every Form 4 that uniQure N.V. (QURE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow QURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QURE filings page.
uniQure N.V.’s CEO Matthew C. Kapusta exercised stock options and sold shares in a pre-planned trade. On July 2, 2026, he exercised options for 21,082 Ordinary Shares at an exercise price of $19.39 per share and converted them into common equity.
That same day, he sold 21,082 Ordinary Shares in three open-market transactions at reported weighted average prices of $44.43, $45.43, and $45.89, with actual sale prices ranging from $44.10 to $46.10. Following these transactions, he directly owned 519,227 Ordinary Shares. The filing states the trades were executed under a Rule 10b5-1 sales plan adopted on October 5, 2025, indicating they were pre-scheduled.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On June 30, 2026, he sold a total of 30,000 Ordinary Shares in open-market sales at weighted average prices of $46.40 and $46.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised stock options to acquire 10,000 Ordinary Shares at a $5.59 exercise price, reducing his option position tied to that grant. Following these transactions, he directly owns 148,235 Ordinary Shares and holds 50,500 stock options expiring on March 1, 2034.
uniQure N.V. director Jack Kaye reported option exercises and share sales. On June 30, 2026, he exercised stock options for a total of 21,167 Ordinary Shares at exercise prices of $20.18 and $37.00, then sold the same number of shares in open-market transactions around $46.43–$46.49 per share. These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025. After these transactions, he directly owned 25,996 Ordinary Shares.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an open-market sale of 1,434 ordinary shares at a weighted average price of $46.86 per share. The shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes, and were not a discretionary trade. Following this transaction, he holds 168,235 shares directly.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported option exercises and share sales in Ordinary Shares. On June 24–25, 2026, he exercised stock options to acquire 32,844 shares at $31.71 per share and sold 35,412 shares in open-market transactions around $50 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 5, 2025. Following these transactions, he directly holds 519,227 Ordinary Shares.
uniQure N.V.’s CEO and Managing Director Matthew C. Kapusta reported a combination of share sales and option exercises in uniQure N.V. ordinary shares. On June 17–18, 2026, he sold an aggregate of 206,100 ordinary shares in multiple open‑market transactions and exercised stock options covering 67,237 ordinary shares.
Sale prices were reported as weighted averages, with underlying trades occurring in ranges disclosed in the footnotes. The filing states these transactions were carried out under a Rule 10b5‑1 sales plan adopted on October 5, 2025. Following the transactions, Kapusta directly owned 521,795 ordinary shares, and the derivative section in this filing shows no remaining stock options related to these exercises.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. On June 17, 2026, he exercised stock options for 11,685 shares at strike prices of $19.39 and $31.71 per share.
The same total of 11,685 shares was then sold in open-market transactions at weighted average prices of $42.60, $43.66, and $47.08 per share. The filing states that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026.
uniQure N.V. director Jack Kaye exercised stock options and sold the resulting shares in a coordinated transaction. On June 17, 2026, he exercised options for 5,295 Ordinary Shares at $31.71 per share and then sold the same 5,295 shares in the open market at a weighted average price of $42.57, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, Kaye directly holds 25,996 Ordinary Shares of uniQure. The exercised stock option, which vested in full on January 25, 2020 and had an expiration date of January 25, 2029, now shows zero remaining derivative balance.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. He exercised stock options for 10,000 shares at $8.49 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $27.85 per share. After these transactions, he directly holds 43,254 Ordinary Shares. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026, and that the sale prices ranged from $27.58 to $28.05.
uniQure N.V. Chief Legal Officer Jeannette Potts reported an open-market sale of 5,237 ordinary shares at a weighted average price of about $27.67 per share. The shares were sold automatically upon RSU vesting solely to cover estimated withholding taxes, and she continues to hold 133,246 shares directly.
uniQure N.V. director David D. Meek reported a mix of equity awards and a small share sale. He received 7,550 restricted share units under the company’s 2014 Share Incentive Plan, each representing one Ordinary Share that vests in full on the first anniversary of the grant, subject to continued service.
Meek was also granted stock options for 13,980 Ordinary Shares at an exercise price of $26.82 per share, vesting 100% after one year and expiring on June 10, 2036. In a separate transaction, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 solely to cover estimated withholding taxes upon RSU vesting, pursuant to automatic instructions, leaving him with 39,747 shares held directly.
uniQure N.V. director Robert Gut reported a mix of equity grants, option exercises, and share sales in Ordinary Shares. On June 10, 2026, he received 7,550 restricted share units at no cost and a stock option for 13,980 shares with a $26.82 exercise price expiring on June 10, 2036. He also exercised options for 2,645 shares at a $16.04 exercise price.
Across June 10–11, 2026, Gut sold 10,278 shares in open‑market transactions at weighted average prices around the mid‑$26 range, including 2,645 shares sold solely to cover estimated withholding taxes upon RSU vesting. The remaining sales were executed under a Rule 10b5‑1 trading plan adopted on July 8, 2025. After these transactions, he directly holds 32,259 Ordinary Shares.
uniQure N.V. Chief Customer & Strat Officer Kylie O’Keefe reported a tax-related share sale. On June 11, 2026, she sold 15,936 ordinary shares at a weighted average price of $27.06 per share in open-market transactions.
The footnotes state the shares were sold automatically upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and the sale was not a discretionary trade. After these transactions, she directly holds 108,864 ordinary shares.
uniQure N.V. director Jeremy P. Springhorn reported a mix of equity awards and a small share sale. On June 10, he received 7,550 restricted share units, each representing one Ordinary Share, which vest 100% on the first anniversary of grant, and 13,980 stock options with a $26.82 exercise price expiring in 2036, also vesting after one year.
On June 11, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 solely to cover estimated withholding taxes upon RSU vesting under automatic instructions, not as a discretionary trade. Following these transactions, he directly holds 43,251 Ordinary Shares.
uniQure N.V. director Leonard E. Post reported routine equity compensation and a small tax-related sale. On June 10, he received 7,550 restricted share units, each representing one Ordinary Share, and a grant of 13,980 stock options exercisable at $26.82 per share, both vesting in full on the first anniversary of the grant.
On June 11, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 to cover estimated withholding taxes upon RSU vesting, under automatic sale instructions and not as a discretionary trade. After these transactions, Post directly owns 35,494 Ordinary Shares.
uniQure N.V. director Jack Kaye reported a mix of equity grants and a small share sale. He received 7,550 restricted share units under the company’s 2014 Share Incentive Plan, each representing one Ordinary Share, vesting 100% one year after the grant date.
He was also granted a stock option for 13,980 Ordinary Shares at an exercise price of $26.82, vesting in full on the first anniversary of grant and expiring in 2036. After RSU vesting, 1,993 shares were automatically sold at a weighted average price of $27.06 solely to cover estimated withholding taxes, not as a discretionary trade. Following these transactions, Kaye directly holds 25,996 Ordinary Shares.
uniQure N.V. director Rachelle Suzanne Jacques reported a mix of equity compensation and a small tax-related sale of Ordinary Shares. She sold 1,993 shares at a weighted average price of $27.06 per share to cover estimated withholding taxes when restricted share units vested, under automatic, non-discretionary sale instructions. She also received 7,550 restricted share units and 13,980 stock options with a $26.82 exercise price, both vesting 100% on the first anniversary of the grant date, subject to continued service. Following these transactions, she directly holds 33,903 Ordinary Shares.
uniQure N.V. director Balachandran Madhavan reported routine equity compensation and related tax sales. He was granted 7,550 restricted share units, each representing one Ordinary Share, and 13,980 stock options with a $26.82 exercise price, both vesting 100% on the first anniversary of the grant date subject to continued service. Upon vesting of earlier restricted share units, 1,993 shares were sold at a weighted average price of $27.06, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owns 43,254 Ordinary Shares and holds the new unvested options.
uniQure N.V. director Kaye Jack reported an option exercise paired with a share sale. On June 3, 2026, Jack exercised stock options to acquire 2,645 Ordinary Shares at $16.04 per share and sold 2,645 Ordinary Shares in open-market transactions at an average price of $30.01 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After the trades, Jack directly owned 20,439 Ordinary Shares, and the exercised stock option for 2,645 shares, which had vested in full on February 24, 2023, was fully used.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On May 8, 2026, he sold a total of 45,000 Ordinary Shares in open-market transactions at weighted-average prices around $25.00–$25.29, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised 25,000 stock options with a $5.59 exercise price, receiving an equal number of Ordinary Shares. After these transactions, he directly held 169,669 Ordinary Shares and 60,500 stock options expiring on March 1, 2034, indicating he retains a substantial equity stake.
uniQure N.V. reported that Chief Customer & Strategy Officer Kylie O'Keefe received new equity awards. On March 4, 2026, she was granted stock options for 31,900 shares at an exercise price of $0.00 per share and 19,800 ordinary shares as restricted share units.
The restricted share units vest in three equal annual installments of one-third each, starting on the first anniversary of the grant date, subject to her continued relationship with the company. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
uniQure N.V. CEO and managing director Matthew C. Kapusta reported new equity compensation grants and a small related share sale. He was granted stock options for 113,800 shares at an exercise price of $0.00 per share and 70,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of the grant date, subject to his continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested. In a separate transaction, 14,581 ordinary shares were sold at a weighted average price of $9.06 per share, within a range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Medical Officer Walid Abi-Saab reported new equity awards and a small automatic share sale. He was granted stock options for 67,200 shares at an exercise price of $0.00 and 41,700 restricted share units, each representing the right to receive one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, subject to continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
Upon vesting of restricted share units, 808 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owned 189,669 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported a mix of equity awards and an automatic share sale. She received a grant of 57,200 stock options with an exercise price of $0.00 per share and 35,400 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, contingent on her continued service. The stock options vest 25% after one year and 6.25% quarterly thereafter. In connection with vesting, 3,412 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported a mix of equity awards and an automatic tax-related sale. On March 4, 2026, he received a stock option for 63,900 shares at an exercise price of $0.00 and a grant of 39,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of grant, subject to his continued relationship with the company. On the same date, 12,000 ordinary shares were sold at a weighted average price of $9.06 per share, within a price range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an automatic open-market sale of 34,437 ordinary shares on March 2, 2026 at an average price of $9.95 per share. The filing explains the shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic instructions, so the sale was not a discretionary trade. After this transaction, Kapusta held 604,639 ordinary shares. The reported price reflects a weighted average from multiple trades between $9.67 and $10.25 per share.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported an automatic tax-related share sale. On March 2, 2026, he sold 12,532 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic sale instructions in the RSU agreement, meaning the sale was not a discretionary trade. Following the transaction, he directly owned 198,981 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported an automatic sale of 8,578 ordinary shares. The shares were sold on March 2, 2026 in open-market transactions at a weighted average price of $9.95 per share.
According to the disclosure, the sale occurred upon the vesting of restricted share units and was made solely to cover estimated withholding taxes under automatic sale instructions, meaning it was not a discretionary trade by Potts. Following these transactions, she directly owned 106,495 ordinary shares of uniQure N.V.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an automatic sale of 1,660 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and were not a discretionary trade. After this transaction, Abi-Saab直接 owns 148,777 ordinary shares. The sale price reflected multiple trades between $9.67 and $10.25.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an open-market sale of 12,378 ordinary shares of the company at a weighted average price of $23.86 per share. The shares were sold automatically upon the vesting of restricted share units solely to cover estimated withholding taxes, under pre-set sale instructions, and not as a discretionary trade. After this transaction, Kapusta directly held 639,076 ordinary shares of uniQure.
uniQure N.V. Chief Financial Officer Christian Klemt reported an open-market sale of 6,217 ordinary shares of the company. The shares were sold at a weighted average price of $23.86 per share and were linked to the vesting of restricted share units.
According to the disclosure, the shares were sold solely to cover estimated withholding taxes under automatic sale instructions in the relevant restricted share unit agreement, meaning the transaction was not a discretionary trade by the executive. After this tax-related sale, Klemt still directly owns 211,513 ordinary shares.
uniQure director Robert Gut reported option exercises and share sales in the company’s ordinary shares. On January 12, 2026, he exercised a stock option for 17,810 ordinary shares at $14.08 per share, converting derivative securities into directly held stock.
On the same date, he sold ordinary shares in several transactions: 17,310 shares at a weighted average price of $24.39 (with individual sale prices between $24.02 and $25.00), 500 shares at a weighted average price of $25.03 (with prices between $25.02 and $25.04), and 7,803 shares at $25.09. After these trades, he directly owned 32,342 ordinary shares. All transactions were carried out under a Rule 10b5-1 trading plan adopted on July 8, 2025.
uniQure N.V. director Jack Kaye reported exercising stock options and selling shares of the company on January 9, 2026. He exercised a stock option to buy 6,390 Ordinary Shares at an exercise price of $19.39 per share, then sold the same 6,390 Ordinary Shares at a weighted average price of $27.28 per share under transaction code "S".
These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025, as described in the footnotes. After the reported transactions, Kaye directly owned 20,439 Ordinary Shares of uniQure N.V.
uniQure N.V. (QURE) disclosed insider transactions by a director on a Form 4 dated 11/06/2025. The reporting person exercised stock options for 15,840 ordinary shares at an exercise price of $4.57 (code M), then reported two open-market sales (code S): 15,840 shares at a weighted average price of $27.22 and 15,594 shares at $27.30. Following these transactions, 40,145 shares were beneficially owned directly.
The transactions were effected under a Rule 10b5-1 plan adopted on July 8, 2025. The filing notes footnote adjustments to prior reported holdings, and states the first sale’s weighted average reflects multiple trades between $27.00 and $27.38. The option covered 15,840 underlying shares, vested in full on June 19, 2025, and carries an expiration date of 06/19/2034.
uniQure N.V. (QURE) disclosed that a director executed option exercises and same‑day sales on 11/04/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The director exercised 10,000 options at $7.37, 11,000 at $5.37, and 17,810 at $14.08, then sold equivalent ordinary shares at weighted average prices of $30.36, $30.34, and $30.33, respectively. Following these transactions, the director beneficially owned 20,439 ordinary shares, held directly.